Evidence map›Paper›PMID 29978303›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2018

Incidence, course, and outcome of Clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantation.

Małgorzata Salamonowicz, T Ociepa, J Frączkiewicz, A Szmydki-Baran, M Matysiak, K Czyżewski, M Wysocki, P Gałązka, P Zalas-Więcek, N Irga-Jaworska and 35 more

Open access · hybridAbstract read
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Prevalence ofFrontiers in cellular and infection microbiology · 2022
    Pooled it
  3. Article
  4. Article
  5. Article
  6. The need for evolution in the management of febrile neutropenia in pediatric cancer: TRIIO KIDS update.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  7. Pediatric gastroenterology, hepatology & nutrition · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2021
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors at 15 institutions in 1 country.

Małgorzata SalamonowiczDepartment of Pediatric Stem Cell Transplantation, Hematology and Oncology, Medical University, Wroclaw, Borowska Street 213, 50-556, Wrocław, Poland. msalamonowicz@poczta.onet.pl.ORCID http://orcid.org/0000-0003-1736-3177
T OciepaDepartment of Pediatric Hemato-Oncology and Gastroenterology, Pomeranian Medical University, Szczecin, Poland.
J FrączkiewiczDepartment of Pediatric Stem Cell Transplantation, Hematology and Oncology, Medical University, Wroclaw, Borowska Street 213, 50-556, Wrocław, Poland.
A Szmydki-BaranDepartment of Pediatric Hematology and Oncology, Medical University, Warszawa, Warszawa, Poland.
M MatysiakDepartment of Pediatric Hematology and Oncology, Medical University, Warszawa, Warszawa, Poland.
K CzyżewskiDepartment of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.
M WysockiDepartment of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.
P GałązkaDepartment of Pediatric Surgery, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.
P Zalas-WięcekDepartment of Microbiology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.
N Irga-JaworskaDepartment of Pediatrics, Hematology and Oncology, Medical University, Gdansk, Gdansk, Poland.
E DrożyńskaDepartment of Pediatrics, Hematology and Oncology, Medical University, Gdansk, Gdansk, Poland.
O Zając-SpychałaDepartment of Pediatric Oncology, Hematology and Transplantology, University of Medical Sciences, Poznan, Poland.
J WachowiakDepartment of Pediatric Oncology, Hematology and Transplantology, University of Medical Sciences, Poznan, Poland.
O Gryniewicz-KwiatkowskaDepartment of Oncology, Children's Memorial Health Institute, Warszawa, Poland.
A Czajńska-DeptułaDepartment of Oncology, Children's Memorial Health Institute, Warszawa, Poland.
B Dembowska-BagińskaDepartment of Oncology, Children's Memorial Health Institute, Warszawa, Poland.
L Chełmecka-WiktorczykDepartment of Pediatric Oncology and Hematology, University Children's Hospital, Jagiellonian University Collegium Medicum, Krakow, Poland.
W BalwierzDepartment of Pediatric Oncology and Hematology, University Children's Hospital, Jagiellonian University Collegium Medicum, Krakow, Poland.
M BartnikDepartment of Pediatric Hemato-Oncology and Gastroenterology, Pomeranian Medical University, Szczecin, Poland.
K ZielezińskaDepartment of Pediatric Hemato-Oncology and Gastroenterology, Pomeranian Medical University, Szczecin, Poland.
T UrasińskiDepartment of Pediatric Hemato-Oncology and Gastroenterology, Pomeranian Medical University, Szczecin, Poland.
R TomaszewskaDepartment of Pediatric Hematology and Oncology, Silesian Medical University, Zabrze, Poland.
T SzczepańskiDepartment of Pediatric Hematology and Oncology, Silesian Medical University, Zabrze, Poland.
M PłonowskiDepartment of Pediatric Oncology and Hematology, Medical University, Bialystok, Bialystok, Poland.
M Krawczuk-RybakDepartment of Pediatric Oncology and Hematology, Medical University, Bialystok, Bialystok, Poland.
F PierlejewskiDepartment of Pediatric Oncology, Hematology and Diabetology, Medical University, Lodz, Lodz, Poland.
W MłynarskiDepartment of Pediatric Oncology, Hematology and Diabetology, Medical University, Lodz, Lodz, Poland.
Z Gamrot-PykaDivision of Pediatric Hematology and Oncology, Chorzow Pediatric and Oncology Center, Chorzow, Poland.
M WoszczykDivision of Pediatric Hematology and Oncology, Chorzow Pediatric and Oncology Center, Chorzow, Poland.
Z MałasDivision of Pediatric Hematology and Oncology, Children Hospital, Olsztyn, Olsztyn, Poland.
W BadowskaDivision of Pediatric Hematology and Oncology, Children Hospital, Olsztyn, Olsztyn, Poland.
A Urbanek-DądelaDivision of Pediatric Hematology and Oncology, Children Hospital, Kielce, Kielce, Poland.
G KarolczykDivision of Pediatric Hematology and Oncology, Children Hospital, Kielce, Kielce, Poland.
W StolpaDivision of Pediatric Oncology, Hematology and Chemotherapy, Department of Pediatric, Silesian Medical University, Katowice, Poland.
G Sobol-MilejskaDivision of Pediatric Oncology, Hematology and Chemotherapy, Department of Pediatric, Silesian Medical University, Katowice, Poland.
A Zaucha-PrażmoDepartment of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical University, Lublin, Lublin, Poland.
J KowalczykDepartment of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical University, Lublin, Lublin, Poland.
J GoździkStem Cell Transplant Center, University Children's Hospital, Department of Clinical Immunology and Transplantology, Jagiellonian University Collegium Medicum, Krakow, Poland.
E GorczyńskaDepartment of Pediatric Stem Cell Transplantation, Hematology and Oncology, Medical University, Wroclaw, Borowska Street 213, 50-556, Wrocław, Poland.
K JermakowDepartment of Microbiology, Medical University, Wroclaw, Wroclaw, Poland.
A KrólDepartment of Pediatric Stem Cell Transplantation, Hematology and Oncology, Medical University, Wroclaw, Borowska Street 213, 50-556, Wrocław, Poland.
A ChybickaDepartment of Pediatric Stem Cell Transplantation, Hematology and Oncology, Medical University, Wroclaw, Borowska Street 213, 50-556, Wrocław, Poland.
M UssowiczDepartment of Pediatric Stem Cell Transplantation, Hematology and Oncology, Medical University, Wroclaw, Borowska Street 213, 50-556, Wrocław, Poland.
K KałwakDepartment of Pediatric Stem Cell Transplantation, Hematology and Oncology, Medical University, Wroclaw, Borowska Street 213, 50-556, Wrocław, Poland.
J StyczyńskiDepartment of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.
Wroclaw Medical University · PLNicolaus Copernicus University · PLMedical University of Silesia · PLPomeranian Medical University · PLChildren's Memorial Health Institute · PLJagiellonian University · PLGdańsk Medical University · PLKielce University of Technology · PLLublin Oncology Center · PLMedical University of Białystok · PLMedical University of Lodz · PLMedical University of Lublin · PLMedical University of Warsaw · PLPoznan University of Medical Sciences · PLUniversity of Computer Sciences and Economics in Olsztyn · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clostridium difficile infection (CDI) is one of the most common causes of nosocomial infectious diarrhea in children during anticancer therapy or undergoing hematopoietic stem cell transplantation (HSCT) in Europe. Immunosuppression in these patients is a risk factor for CDI. Malignant diseases, age, acute graft-versus-host disease (aGVHD), HLA mismatch, or use of total body irradiation may play an important role in CDI course. The aim of this study was to evaluate the incidence, course, and outcome of CDI in children treated for malignancy or undergoing HSCT. Between 2012 and 2015, a total number of 1846 patients were treated for malignancy in Polish pediatric oncological centers (PHO group) and 342 underwent transplantation (HSCT group). In PHO group, episodes of CDI occurred in 210 patients (14%). The incidence of CDI was higher in patients with hematological malignancies in comparison to that with solid tumors. Patients with acute myeloblastic leukemia had shorter time to episode of CDI than those with acute lymphoblastic leukemia. Patients over 5 years and treated for acute leukemia had more severe clinical course of disease in PHO group. In HSCT group, CDI occurred in 29 (8%) patients. The incidence of CDI was higher in patients transplanted for acute leukemia. The recurrence rate was 14.7% in PHO and 20.7% in HSCT patients. CDI incidence was highest in patients with hematological malignancies. Most of patients experienced mild CDI. Age < 5 years and diagnosis other than acute leukemia were the positive prognostic factors influencing clinical CDI course.

Indexed as

ChildChild, PreschoolClostridioides difficileClostridium InfectionsFemaleHematologic NeoplasmsHematopoietic Stem Cell TransplantationHospitals, PediatricHumansIncidenceInfantLeukemia, Myeloid, AcuteMalePolandPrecursor Cell Lymphoblastic Leukemia-LymphomaRecurrenceChildrenClostridium difficileHematopoietic stem cell transplantationMalignant diseasesPediatric hematology and oncology

Identifiers

PMID29978303
PMCPMC6133038
OpenAlexW2854112297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.